Bayer Escapes China Slowdown While Integrating Consumer Product Businesses
This article was originally published in The Tan Sheet
Executive Summary
OTC allergy remedies, contraceptive pills and skin care help Bayer continue its growth momentum in China despite an economic slowdown. Integrating OTC and TCM brands from local firm Dihon and global pharma Merck & Co., Bayer forecasts a smooth ride ahead.
You may also be interested in...
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.